AGIOS PHARMACEUTICALS, INC. AGIO

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.

The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. Mitapivat is approved in the United States by the U.S. Food and Drug Administration, or FDA, under the brand name AQVESME™ for the treatment of anemia in adults with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia and in Saudi Arabia under the brand name PYRUKYND® for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Mitapivat is also approved under the brand name PYRUKYND® in the United States by the FDA for the treatment of hemolytic anemia in adults with PK deficiency and in the European Union, or EU, and Great Britain for the treatment of PK deficiency in adults.

Last close 37.00 2026-10-23
Market cap $2.21B 2026-06-30 share count
52-week range 22.24 - 46.00

Valuation FY2025 figures against the last close

P/S40.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-7.12

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $54.0M$36.5M$26.8M$14.2M$0$0$117.9M$94.4M$43.0M$69.9M
Cost of revenue $6.3M$4.2M$2.9M$1.7M$0$0$1.3M$1.4M$0$0
Gross profit $47.7M$32.3M$23.9M$12.5M$0$0$116.6M$93.0M$43.0M$69.9M
R&D $339.5M$301.3M$295.5M$279.9M$257.0M$220.8M$214.3M$341.3M$292.7M$220.2M
SG&A $180.3M$156.8M$119.9M$121.7M$121.4M$115.1M$102.0M$114.1M$71.1M$50.7M
Total operating expenses $526.2M$462.2M$418.3M$403.3M$378.4M$335.9M$316.3M$456.9M$363.8M$270.9M
Operating income -$472.1M-$425.7M-$391.5M-$389.0M-$378.4M-$335.9M-$316.3M-$362.5M-$320.8M-$201.0M
Pre-tax income -$413.8M$718.0M-$352.1M-$231.8M-$356.5M-$329.3M-$301.4M-$346.0M-$314.7M-$198.5M
Income tax $1.0M$44.2M$0$0——$0$0$0$0
Net income -$413.0M$674.0M-$352.0M-$232.0M$1.60B-$327.4M-$411.5M-$346.0M-$314.7M-$198.5M
EPS, basic -7.1211.86-6.33-4.2326.55-4.74-6.86———
EPS, diluted -7.1211.64-6.33-4.2326.55-4.74-6.86-6.03-6.75-5.07
Shares, diluted (wtd. avg.) 58.0M57.9M55.7M54.8M60.4M69.0M60.0M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $89.1M$76.2M$88.2M$139.3M$203.1M$127.4M$80.9M$70.5M$102.7M$160.8M
Short-term investments $765.3M$817.5M$688.7M$643.9M$816.9M$445.5M$483.9M$514.8M—$380.6M
Inventory $32.9M$27.6M$19.1M$8.5M$0$14.7M$7.3M$869.0K$0—
Total current assets $942.1M$965.6M$833.8M$832.8M$1.06B$636.7M$611.7M$613.8M$445.3M$559.9M
Property, plant and equipment $10.8M$11.7M$15.4M$23.0M$28.9M$30.8M$31.5M$24.3M$24.4M$25.3M
Total assets $1.30B$1.66B$937.1M$1.24B$1.44B$853.0M$890.7M$858.5M$614.4M$619.1M
Accounts payable $18.4M$16.6M$9.8M$18.6M$16.7M$17.7M$21.9M$17.9M$22.8M$17.1M
Total current liabilities $82.2M$81.2M$68.0M$62.6M$59.8M$94.4M$92.9M$93.5M$94.9M$88.4M
Total liabilities $104.1M$122.2M$126.1M$137.9M$145.8M$453.5M$250.2M$170.9M$238.9M$260.5M
Retained earnings -$561.7M-$148.9M-$822.6M-$470.6M-$238.8M-$1.84B-$1.52B-$1.10B-$758.6M-$483.2M
Total equity $1.19B$1.54B$811.0M$1.10B$1.29B$399.5M$640.5M$687.5M$375.5M$358.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$373.0M-$389.8M-$296.1M-$309.5M-$407.3M-$290.8M-$370.6M-$304.4M-$285.2M$38.6M
Depreciation and amortisation $5.2M$5.7M$6.6M$8.4M$8.8M$9.4M$8.0M$7.2M$6.4M$5.7M
Stock-based compensation $52.6M$42.8M$44.8M$49.3M$53.5M$61.6M$58.0M$73.4M$47.8M$42.1M
Capital expenditure $4.3M$1.7M$999.0K$4.9M$5.7M$14.1M$12.0M$7.0M$4.6M$9.9M
Investing cash flow $377.2M$363.4M$239.6M$243.3M$1.25B$75.7M$91.4M-$273.8M-$57.9M-$119.3M
Financing cash flow $8.7M$14.4M$5.4M$2.4M-$765.8M$261.5M$289.6M$546.0M$285.1M$169.8M
Buybacks ————$802.5M—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177086.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B Revenue, FY2016: 69.9M Gross profit, FY2016: 69.9M Net income, FY2016: -198.5M Revenue, FY2017: 43M Gross profit, FY2017: 43M Net income, FY2017: -314.7M Revenue, FY2018: 94.4M Gross profit, FY2018: 93M Net income, FY2018: -346M Revenue, FY2019: 117.9M Gross profit, FY2019: 116.6M Net income, FY2019: -411.5M Revenue, FY2020: 0 Gross profit, FY2020: 0 Net income, FY2020: -327.4M Revenue, FY2021: 0 Gross profit, FY2021: 0 Net income, FY2021: 1.6B Revenue, FY2022: 14.2M Gross profit, FY2022: 12.5M Net income, FY2022: -232M Revenue, FY2023: 26.8M Gross profit, FY2023: 23.9M Net income, FY2023: -352M Revenue, FY2024: 36.5M Gross profit, FY2024: 32.3M Net income, FY2024: 674M Revenue, FY2025: 54M Gross profit, FY2025: 47.7M Net income, FY2025: -413M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $69.9M $43.0M $94.4M $117.9M $0 $0 $14.2M $26.8M $36.5M $54.0M
Gross profit $69.9M $43.0M $93.0M $116.6M $0 $0 $12.5M $23.9M $32.3M $47.7M
Net income -$198.5M -$314.7M -$346.0M -$411.5M -$327.4M $1.60B -$232.0M -$352.0M $674.0M -$413.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%